Amyloid, Tau Levels Continuing to Fall With Aduhelm’s Long-term Use

Home / Alzheimer's / Amyloid, Tau Levels Continuing to Fall With Aduhelm’s Long-term Use
Amyloid, Tau Levels Continuing to Fall With Aduhelm’s Long-term Use
March 25, 2022March 25, 2022
0

Aduhelm (aducanumab) continues to clear away amyloid plaques and tangled fibers made up of tau — two abnormal protein aggregates that build in the brain of those with Alzheimer’s disease — after nearly two and a half years of treatment, Biogen, which markets the treatment, reports. It also announced plans to begin patient screening for ENVISION, a Phase 4 post-marketing study of Aduhelm, in May. The updated findings come from long-term extensions of EMERGE (NCT02484547) and ENGAGE…

You must be logged in to read/download the full post.

The post Amyloid, Tau Levels Continuing to Fall With Aduhelm’s Long-term Use appeared first on BioNewsFeeds.